In this fast-moving industry, BioCT keeps policy makers and influencers abreast of the latest developments and changing needs of the bioscience community.
Our mission is to provide education and advocacy for Connecticut’s bioscience and life science communities at the policy level and ensure synergy of action and alignment of state and federal initiatives that have a significant impact on our members.
BioCT’s advocacy wins at the state level include:
Federal advocacy focuses on the continuing robustness of these agencies:
The Government Affairs Committee is comprised of BioCT board members, industry executives and business advisors including the government relations firm of Rome, Smith & Lutz, which has deep expertise in matters impacting our industry.
President & CEO,
Senior Manager, State Government Affairs,
Bristol Myers Squibb
Kathy Andrews Bilotas
Director of State Government Affairs,
Partner, Tax Services,
Fiondella, Milone & LaSaracina
Chief Financial Officer
State Government Affairs, Regional Director,
Director, US Government Relations/Corporate Affairs,
Associate Vice President for Federal Relations,
Director, State Government Relations,
Rome, Smith & Lutz
Senior Director, State Government Affairs,
Regional Director, State Government Affairs,
Marie DeSanto Schweitzer
Director, Government Relations for Health Affairs
University of Connecticut
Director, Alliance Development
Bristol Myers Squibb
Rome Smith & Lutz
State Government Affairs Manager, East Coast,
March 25, 2022
We support the bill and respectfully ask for a modification of the existing language to expand the refund exchange from the current level of 65% to 90% as well as increase the current credit percentage from 70% to 90% for the biotech industry.
March 22, 2022
Rarely in our history has the power of science and innovation to keep our communities safe and healthy been in such clear focus.
March 8, 2022
We respectfully opposes SB 260, creation of a Prescription Drug Affordability Board, tasked with reviewing prescription drug costs and setting upper payment limits for specified prescription drugs.
March 9, 2022
BioCT and our members are very supportive in passing this bill.
March 1, 2022
We recommend Connecticut be on the cutting edge and take a holistic approach to drug pricing that truly reduces patient out of pocket costs, while also supporting the entire bio/pharma industry and encourages continued innovation.
July 14, 2021
May 12, 2021
We believe the legislation, though well-intentioned, is flawed on at least five fronts.
May 8, 2021
In the recent letter to President Biden from BIO’s President & CEO, Dr. Michelle McMurry-Heath, BIO suggests the establishment of a COVID Global Strategy for Harnessing Access Reaching Everyone (SHARE) Program, to be implemented immediately.
April 20, 2021
On behalf of BIO, BioCT and our Board of Directors, as shown, we are writing in support of SB 1099, An Act Authorizing Bonds of the State for a Research Faculty Recruitment and Hiring Program by the University of Connecticut To Encourage the Creation of New Business Venture.